Sarcoidosis is a multisystem disorder with variable prognosis - Information for treating physicians

Swiss Medical Weekly

Volumn 136, Issue 13-14, 2006, Pages 201-209

  Wiegand, Jan A ^a   Brutsche, Martin H ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Apoptosis; Gene expression; Infliximab; Prognosis; Sarcoidosis; Tumour necrosis factor alpha

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PENTOXIFYLLINE; PREDNISOLONE; PREDNISONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALLERGIC REACTION; BIOPSY; BLOOD TESTIS BARRIER; CANCER; CHRONIC GRANULOMATOUS DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CYSTITIS; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; EUROPE; EYE TOXICITY; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INSOMNIA; KIDNEY FAILURE; LIVER TOXICITY; LUNG FIBROSIS; LYMPHOMA; MORBIDITY; NAUSEA; NEUTROPENIA; OSTEOPOROSIS; PERIPHERAL NEUROPATHY; PREVALENCE; PROGNOSIS; SARCOIDOSIS; SCAR FORMATION; SHORT SURVEY; SOMNOLENCE; ULTRASOUND; DIAGNOSTIC IMAGING; MEDICAL RESEARCH; REVIEW;

BIOMEDICAL RESEARCH; BIOPSY; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; HUMANS; PROGNOSIS; SARCOIDOSIS;

EID: 33646167704     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (89)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-55.
2. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997;336:1224-34.
3. Rybicki BA, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997;145:234-41.
4. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003;361:1111-8.
5. Thomas KW, Hunninghake GW. Sarcoidosis. JAMA 2003; 289:3300-3.
6. Hiraga Y. An epidemiological study of clustering of sarcoidosis cases. Nippon Rinsho 1994;52:1438-42.
7. Pietinalho A, et al. Familial sarcoidosis in Finland and Hokkaido, Japan - a comparative study. Respir Med 1999;93: 408-12.
8. Hills SE, Parkes SA, Baker SB. Epidemiology of sarcoidosis in the Isle of Man - 2: Evidence for space-time clustering. Thorax 1987;42:427-30.
9. Parkes SA, et al. Epidemiology of sarcoidosis in the Isle of Man - 1: A case controlled study. Thorax 1987;42:420-6.
10. Brown ST, et al. Recovery of cell wall-deficient organisms from blood does not distinguish between patients with sarcoidosis and control subjects. Chest 2003;123:413-7.
11. Almenoff P, et al. Growth of acid fast L forms from the blood of patients with sarcoidosis. Thorax 1996;51:530-3.
12. Ang SC, Moscovic EA. Cross-reactive and species specific Mycobacterium tuberculosis antigens in the immunoprofile of Schaumann bodies: a major clue to the etiology of sarcoidosis. Histol Histopathol 1996;11:125-34.
13. Alavi HA, Moscovic EA. Immunolocalization of cell-wall-deficient forms of Mycobacterium tuberculosis complex in sarcoidosis and in sinus histiocytosis of lymph nodes draining carcinoma. Histol Histopathol 1996;11:683-94.
14. Jones RE, Chatham WW. Update on sarcoidosis. Curr Opin Rheumatol 1999;11:83-7.
15. Rybicki BA, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001;164:2085-91.
16. Baughman RP, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885-9.
17. Schurmann M, et al. Familial sarcoidosis is linked to the major histocompatibility complex region. Am J Respir Crit Care Med 2000;162:861-4.
18. Rutherford RM, et al. HLA-DR2 predicts susceptibility and disease chronicity in Irish sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2004;21:191-8.
19. Spagnolo P, et al. C-C chemokine receptor 2 and sarcoidosis: association with Lofgren's syndrome. Am J Respir Crit Care Med 2003;168:1162-6.
20. Valentonyte R, et al. Study of C-C chemokine receptor 2 alleles in sarcoidosis, with emphasis on family-based analysis. Am J Respir Crit Care Med 2005;171:1136-41.
21. Mrazek F, et al. Association of tumour necrosis factor-alpha, lymphotoxin-alpha and HLA-DRB1 gene polymorphisms with Lofgren's syndrome in Czech patients with sarcoidosis. Tissue Antigens 2005;65:163-71.
22. Arbustini E, et al. Polymorphism of angiotensin-converting enzyme gene in sarcoidosis. Am J Respir Crit Care Med 1996; 153:851-4.
23. Maliarik MJ, et al. Angiotensin-converting enzyme gene polymorphism and risk of sarcoidosis. Am J Respir Crit Care Med 1998;158:1566-70.
24. Tomita H, et al. Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis. Am J Respir Crit Care Med 1997;156:255-9.
25. Rybicki BA, et al. Sarcoidosis and granuloma genes: a family-based study in African-Americans. Eur Respir J 2004;24:251-7.
26. Hunninghake GW, et al. Characterization of the inflammatory and immune effector cells in the lung parenchyma of patients with interstitial lung disease. Am Rev Respir Dis 1981;123: 407-12.
27. Hunninghake GW, Crystal RG. Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med 1981;305:429-34.
28. Shigehara K, et al. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol 2001;166: 642-9.
29. Standiford TJ, et al. Macrophage inflammatory protein-1 alpha expression in interstitial lung disease. J Immunol 1993;151: 2852-63.
30. Ziegenhagen MW, Muller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med 2003;253: 18-30.
31. Car BD, et al. Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med 1994; 149:655-9.
32. Girgis RE, et al. Cytokines in the bronchoalveolar lavage fluid of patients with active pulmonary sarcoidosis. Am J Respir Crit Care Med 1995;152:71-5.
33. Ziegenhagen MW, et al. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Investig Med 1998;46:223-31.
34. Iida K, et al. Analysis of T cell subsets and beta chemokines in patients with pulmonary sarcoidosis. Thorax 1997;52:431-7.
35. Kodama X, et al. Expression of RANTES by bronchoalveolar lavage cells in nonsmoking patients with interstitial lung diseases. Am J Respir Cell Mol Biol 1998;18:526-31.
36. Pinkston P, Bitterman PB, Crystal RG. Spontaneous release of interleukin-2 by lung T lymphocytes in active pulmonary sarcoidosis. N Engl J Med 1983;308:793-800.
37. Hunninghake GW, et al. Role of interleukin-2 release by lung T-cells in active pulmonary sarcoidosis. Am Rev Respir Dis 1983;128:634-8.
38. Semenzato G, et al. Immunohistological study in sarcoidosis: evaluation at different sites of disease activity. Clin Immunol Immunopathol 1984;30:29-40.
39. Muller-Quernheim J, et al. Interleukin-2 receptor gene expression by bronchoalveolar lavage lymphocytes in pulmonary sarcoidosis. Am Rev Respir Dis 1989;140:82-8.
40. Agostini C, et al. Phenotypical and functional analysis of natural killer cells in sarcoidosis. Clin Immunol Immunopathol 1985;37:262-75.
41. Rutherford RM, et al. Functional genomics in sarcoidosis - reduced or increased apoptosis? Swiss Med Wkly 2001;131: 459-70.
42. Rabin DL, et al. Sarcoidosis: social predictors of severity at presentation. Eur Respir J 2004;24:601-8.
43. Newman LS, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 2004;170:1324-30.
44. Daweritz C, Brutsche M. Young man with exercise-induced dyspnea. Schweiz Rundsch Med Prax 2001;90:1783-5.
45. Siltzbach LE. Sarcoidosis: clinical features and management. Med Clin North Am 1967;51:483-502.
46. Loddenkemper R, et al. Clinical findings in 715 patients with newly detected pulmonary sarcoidosis - results of a cooperative study in former West Germany and Switzerland. WATL Study Group. Wissenschaftliche Arbeitsgemeinschaft für die Therapie von Lungenkrankheiten. Sarcoidosis Vasc Diffuse Lung Dis 1998;15:178-82.
47. Pietinalho A, et al. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis Vasc Diffuse Lung Dis 1996;13:159-66.
48. Judson MA, et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003;20: 204-11.
49. Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial biopsy for sarcoidosis: a prospective study. Chest 2001;120:109-14.
50. Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial involvement and airway hyperreactivity in patients wih sarcoidosis. Chest 2001;120:881-6.
51. Chapman JT, Mehta AC. Bronchoscopy in sarcoidosis: diagnostic and therapeutic interventions. Curr Opin Pulm Med 2003;9: 402-7.
52. Koerner SK, et al. Transbronchinal lung biopsy for the diagnosis of sarcoidosis. N Engl J Med 1975;293:268-70.
53. Costabel U. Sensitivity and Specificity of BAL findings in sarcoidosis. Sarcoidosis 1992;9(Suppl. 1):211-4.
54. Costabel U. CD4/CD8 ratios in bronchoalveolar lavage fluid: of value for diagnosing sarcoidosis? Eur Respir J 1997;10: 2699-700.
55. Marruchella A, Tondini M. Reliability of bronchoalveolar lavage in the routine clinical assessment of patients with sarcoidosis. A retrospective analysis. Panminerva Med 2002;44: 257-60.
56. Ziegenhagen MW, et al. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 2003;21:407-13.
57. Greco S, et al. Predictive value of BAL cellular analysis in differentiating pulmonary tuberculosis and sarcoidosis. Eur Respir J 2005;26:360-2.
58. Welker L, et al. Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. Eur Respir J 2004;24: 1000-6.
59. Mana J, et al. Excessive thoracic computed tomographic scanning in sarcoidosis. Thorax 1995;50:1264-6.
60. Lynch JP, 3rd, Computed tomographic scanning in sarcoidosis. Semin Respir Crit Care Med 2003;24:393-418.
61. Costabel U. Sarcoidosis: clinical update. Eur Respir J Suppl 2001;32:56s-68s.
62. Drent M, et al. Sarcoidosis: assessment of disease severity using HRCT. Eur Radiol 2003;13:2462-71.
63. Halme M, Piilonen A, Taskinen E. Comparison of endobronchial and transbronchial biopsies with high-resolution CT (HRCIT) in the diagnosis of sarcoidosis. Apmis 2001;109: 289-94.
64. Akira M, et al. Long-term Follow-up CT Scan Evaluation in Patients With Pulmonary Sarcoidosis. Chest 2005;127:185-91.
65. Mana J. Nuclear imaging. 67Gallium, 201thallium, 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography. Clin Chest Med 1997;18:799-811.
66. El-Haddad G, et al. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 2004;34:313-29.
67. Lower EE, et al. The anemia of sarcoidosis. Sarcoidosis 1988;5: 51-5.
68. Studdy PR, Bird R. Serum angiotensin converting enzyme in sarcoidosis - its value in present clinical practice. Ann Clin Biochem 1989;26:13-8.
69. Shorr AF, Torrington KG, Parker JM. Serum angiotensin converting enzyme does not correlate with radiographic stage at initial diagnosis of sarcoidosis. Respir Med 1997;91:399-401.
70. Rutherford RM, et al. Prevalence of coeliac disease in patients with sarcoidosis. Eur J Gastroenterol Hepatol 2004;16:911-5.
71. Judson MA, et al. The diagnostic pathway to sarcoidosis. Chest 2003;123:406-12.
72. Hunninghake GW, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994;149:893-8.
73. Paramothayan XS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005: p. CD001114.
74. Sollberger M, et al. Successful treatment of steroid-refractory neurosarcoidosis with infliximab. J Neurol 2004;251:760-1.
75. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 2001;135:27-31.
76. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:70-4.
77. Baughman RP, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005;128: 1062-47.
78. Utz JP, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003;124:177-85.
79. Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003;30:1864-7.
80. Kolopp-Sarda MN, et al. Discriminative immunophenotype of bronchoalveolar lavage CD4 lymphocytes in sarcoidosis. Lab Invest 2000;80:1065-9.
81. Spagnolo P, et al. C-C Chemokine Receptor 5 Gene Variants in Relation to Lung Disease in Sarcoidosis. Am J Respir Crit Care Med 2005:172:721-8.
82. Agostini C, et al. Role for CXCR6 and its Ligand CXCL16 in the Pathogenesis of T-cell Alveolitis in Sarcoidosis. Am J Respir Crit Care Med 2005.
83. Valentonyte R, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005;37:357-64.
84. Rybicki BA, et al. The BTNL2 Gene and Sarcoidosis Susceptibility in African Americans and Whites. Am J Hum Genet 2005;77:491-9.
85. Rutherford RM, et al. Functional genomics and prognosis in sarcoidosis - the critical role of antigen presentation. Sarcoidosis Vasc Diffuse Lung Dis 2004;21:10-8.
86. Bihl MP, et al. Progressive pulmonary sarcoidosis - a fibroproliferative process potentially triggered by EGR-1 and IL-6. Sarc Vasc Lung Dis 2005: p. In press.
87. Chang B, et al. Depression in sarcoidosis. Am J Respir Crit Care Med 2001;163:329-34.
88. Yeager H, et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:147-53.
89. Bratsche M. MEDICA-Seminar-Beitrag: Lebensqualität und medizinische Betreuung bei Sarkoidose - die Meinung der Betroffenen. Sarkoidose Nachrichten und Berichte, 2002.